Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor

Published:2007-10-15 Issue:20 Volume:67 Page:9887-9893
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Jani Jitesh P.,Finn Richard S.,Campbell Mary,Coleman Kevin G.,Connell Richard D.,Currier Nicolas,Emerson Erling O.,Floyd Eugenia,Harriman Shawn,Kath John C.,Morris Joel,Moyer James D.,Pustilnik Leslie R.,Rafidi Kristina,Ralston Sherry,Rossi Ann Marie K.,Steyn Stefanus J.,Wagner Larry,Winter Steven M.,Bhattacharya Samit K.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

3. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

4. Design, synthesis, and antiproliferative activities of novel substitutedhydrazone/triazolo-linked quinazoline derivatives;Journal of Molecular Structure;2024-06

5. Scalable Synthesis of Cinnamylamines Via the Heck Reaction: Application in the Synthesis of Abamine, Naftifine and Reboxetine;European Journal of Organic Chemistry;2024-04-04